Tweet

Session 207
Biopharma Commercial Alliance Management Challenges

The commercial phase of a biopharma alliance brings a new set of challenges to alliance managers. Our panel of experts shares their insights from a vast range of experiences with commercial alliances on a global scale. Bring your questions and join a lively discussion about:

Moderator:

Panelists:

Andrew Yeomans
Global Alliance Lead
UCB

Global Alliance Leader at UCB, based in Brussels, Belgium, Andrew is focused on optimizing value for significant strategic alliances with Amgen and Sanofi as well as continuing to refine best alliance practices for UCB and its major alliance partnerships. Andrew currently optimizes value as major launches actively take place within his alliance portfolio for his company, that span the globe, with a particular focus on Commercial launch and Development collaborations.

Other positions he has held include Global Director of Alliance Management at Merck-Serono where he was actively involved in leading several key alliances, within Europe, China, Japan, and Korea.

Prior to this, he was instrumental in setting up an Alliance Management function and culture for ALK-Abello A/S as the partner, Schering Plough was preparing for launches in the USA & Canada.

He has over 27 years of global experience in the Pharmaceutical Industry, while his early career was within Corporate Sales and Marketing Leadership positions, focusing on Europe, Asia and North America. During this time as a result of leading a number of successful product launches and Commercial collaborations, he evolved naturally into formal Alliance Management over 14 years ago.

Andrew is highly active within ASAP as a Certified Strategic Alliance Professional, CSAP and has been a member of several Regional Chapters. He has also researched and presented on the subject of cross-cultural influences within the global alliance community on a number of occasions. Andrew is a Registered Pharmacist in the UK and has an MBA from Henley Business School.